Having 60 starters in the trial is a reasonable number, to get an indication of its effectiveness especially with information gained from the bio markers. The delay and possible additional research may enhance a positive result. As a guess this article was formulated by Kempler not David Stamler because of the lack, of additional information shareholders would appreciate.
Having 60 starters in the trial is a reasonable number, to get...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(11.1%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $4.263K | 916.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 69165915 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 38212524 | 21 |
View Market Depth
| Last trade - 15.11pm 05/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |